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Age-associated diseases such as neurodegenerative and cardiovascular disorders are characterized by increased oxidative stress
associated with autophagy dysfunction. Oleuropein aglycone (OA), the main polyphenol found in olive oil, was recently
characterized as an autophagy inducer and a promising agent against neurodegeneration. It is presently unknown whether OA
can have beneficial effects in a model of cardiac stress characterized by autophagy dysfunction. Here, we explored the effects of
OA in cardiomyocytes with overexpression of monoamine oxidase-A (MAO-A). This enzyme, by degrading catecholamine and
serotonin, produces hydrogen peroxide (H2O2), which causes oxidative stress, autophagic flux blockade, and cell necrosis. We
observed that OA treatment counteracted the cytotoxic effects of MAO-A through autophagy activation, as displayed by the
increase of autophagic vacuoles and autophagy-specific markers (Beclin1 and LC3-II). Moreover, the decrease in
autophagosomes and the increase in autolysosomes, indicative of autophagosome-lysosome fusion, suggested a restoration of
the defective autophagic flux. Most interestingly, we found that the ability of OA to confer cardioprotection through autophagy
induction involved nuclear translocation and activation of the transcriptional factor EB (TFEB). Our data provide strong
evidence of the beneficial effects of OA, suggesting its potential use as a nutraceutical agent against age-related pathologies
involving autophagy dysfunction, including cardiovascular diseases.
1. Introduction
The rise in life expectancy has been paralleled by an increased
incidence of age-associated diseases such as neurodegenera-
tive disorders and cardiovascular diseases [1]. Heart failure
(HF) is a multifactorial clinical syndrome characterized by
adverse ventricular remodelling and oxidative stress, which
is considered an essential determinant in the progression of
ventricular dysfunction. In fact, ROS can directly oxidize
proteins involved in contractile activity and consequently
impair ventricular function [2, 3]. Although different sources
contribute to global oxidative stress, the vast majority of cel-
lular ROS originate from the mitochondrial compartment [4,
5]. In addition to the respiratory chain, a class of enzymes
known as monoamine oxidases (MAOs), located at the outer
mitochondrial membrane, have been identified as major
heart sources of hydrogen peroxide (H2O2), a key player in
the onset and progression of cardiac injury [6–8]. MAOs
are FAD-dependent enzymes found in two isoforms, MAO-
A and MAO-B, differing in terms of tissue distribution and
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substrate specificity. MAO-A is responsible for the oxidative
deamination of catecholamines and serotonin in the heart
with production of the corresponding aldehyde, H2O2 and
ammonia. Although the role of each isoform remains to be
investigated, many studies have recently shown that MAO’s
expression and activity were increased in age-associated
chronic cardiac diseases [2, 4, 8, 9].
In the heart, ROS can also interfere with quality control
mechanisms by blocking autophagy and promoting senes-
cence and apoptosis [10]. Autophagy is an intracellular pro-
cess aimed at degrading cytoplasmic components for
removal or recycling [11]. At the molecular level, pathological
conditions such as HF are characterized by the harmful accu-
mulation of damaged mitochondria and misfolded proteins,
probably as a consequence of impairment of the autophagic
flux. In such conditions, autophagy is initially activated as a
survival mechanism, but under overwhelming stress condi-
tions it can become defective, leading to cell damage [12].
Recent studies have investigated the link between MAO,
ROS, and autophagy in HF [8, 13]. Santin et al. [13] reported
that MAO-A overactivity was associated with significant
mitochondrial dysfunction. Indeed, the MAO-A/H2O2 axis
negatively affected the elimination and recycling of mito-
chondria through the autophagosome-lysosome pathway,
resulting in cardiomyocyte death and ultimately HF. The
authors also reported that, in conditions of enhanced
MAO-A activity, the impairment of autophagic flux and
lysosomal function were associated with a lack of nuclear
translocation of transcriptional factor EB (TFEB), a master
regulator of genes involved in the autophagy-lysosomal
pathway. Interestingly, TFEB overexpression counteracted
the deleterious effects of the MAO-A/H2O2 axis by reducing
autophagosome accumulation and cell necrosis [13]. Conse-
quently, restoration of defective autophagy now appears as
an important therapeutic strategy in the context of cardio-
vascular diseases [14, 15].
Several small molecules acting as autophagy modulators,
such as plant polyphenols, or natural compounds present in
fruit and vegetables, have been proposed for their possible
therapeutic applications [16–18]. Among these, oleuropein
aglycone (OA) is the main phenol present in extra virgin
olive oil (EVOO) and is derived from its precursor oleuro-
pein (OLE) by the activity of β-glucosidase released from
olive fruits during crushing [19] or present in human intesti-
nal mucosa [20]. The concentration of OA in EVOO ranges
from 79 to 229mg/kg according to Servili et al. [21] and
depends on different factors such as olive cultivar, ripening
stage at harvesting, and geographic origin of olives. OA has
recently been characterized as an autophagy activator and a
promising agent against neurodegenerative disorders both
in neuroblastoma cell lines and in TgCRND8 mice, a model
of Aβ deposition [22–27]. In this transgenic model, food
supplementation with OA resulted in remarkable plaque
reduction and improvement of cognitive performance by
restoring the compromised autophagic flux [27].
Based on the importance of the autophagy process in HF,
we sought to assess whether OA-induced autophagy is
operative in cardiomyocytes and whether it is protective
against cell damage promoted by the MAO/H2O2 axis.
2. Materials and Methods
2.1. Materials. Oleuropein was from Extrasynthese (Lyon,
France). DMEM (high glucose +GlutaMAX), HAM F-12,
fetal bovine serum (FBS), and horse serum were purchased
from Gibco, Life Technologies. Medium 199, Earle’s salts,
pancreatin, gelatin solution, phenol red (solution), Percoll,
chloroquine (CQ), and almond β-glycosidase were from
Sigma-Aldrich. Collagenase A (Clostridium hystolyticum)
was from Roche. Ad-MAO-A adenovirus was made as previ-
ously described [4]. RFP-GFP-LC3 plasmid was from
Addgene (Cambridge, USA).
2.2. Oleuropein Deglycosylation. Oleuropein deglycosylation
by β-glucosidase was performed according to Konno et al.
[28] with minor modifications. Briefly, a 10mM solution of
oleuropein in 310μl of 0.1M sodium phosphate buffer,
pH7.0, was incubated with 8.90 IU of β-(almond) glycosi-
dase overnight at room temperature. The reaction mixture
was centrifuged at 36,580g for 10min to precipitate OA,
which was then dissolved in dimethyl sulfoxide (DMSO)
with vortexing and sonication. Complete oleuropein deglyco-
sylation was confirmed by assaying the glucose released in
the supernatant with the Glucose (HK) Assay Kit (Sigma).
The mass spectra of oleuropein and of the pellet sample
dissolved in DMSO, obtained in ESI and negative ionization
mode, by a direct infusion in a triple quadrupole (TSQ
Quantum Thermo Finnigan), confirmed the substantial total
recovery of OA in the precipitate (Supplemental Figure 1)
that, chemically, corresponds to a mixture of isomers (data
not shown), also characterized by Diamantakos et al. [29].
The quantity of OA obtained is equimolar to glucose
released. A 50mM OA stock solution in DMSO was stored
at −20°C and diluted immediately before use.
2.3. Primary Cardiomyocyte Cultures, Adenoviral
Transduction, and Treatment. Isolation of neonatal rat
ventricular myocytes was performed in accordance with the
Guide for the Care and Use of Laboratory Animals. The
ventricles were collected from neonatal rats 2–3 days old
and were subjected to serial digestions with type II collage-
nase/pancreatin as previously described [30]. Myocyte
enrichment was performed by centrifugation in a discontin-
uous Percoll gradient, and the resultant suspension of
myocytes was plated in the plating medium (68% DMEM
+GlutaMAX, 17% Medium 199, 10% horse serum, 5% FBS,
and 1.0% antibiotics) onto gelatin-coated culture dishes
[13]. The day after the isolation, the medium was replaced
with complete fresh medium (HAM F-12, 10% FBS, 10%
HS, and 1.0% penicillin/streptomycin).
Adenoviral infection with a replication-deficient adeno-
viral vector expressing MAO-A was performed as
previously described [13]. Ad-MAO-A-transduced cardio-
myocytes were either treated with the MAO-A substrate
tyramine (TYR, 500μM) for 6 h to assess the effects of
MAO-A activation or pretreated with TYR for 2 h before
addition of OA (100μM) for the remaining 4 h in the
culture media (posttreatment).
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2.4. SiRNA-TFEB Transfection. Cardiomyocytes were
silenced with TFEB siRNA oligonucleotides (SMARTpool
ON-TARGETplus, Dharmacon) delivered using the Dhar-
maFECT Duo transfection reagent (Dharmacon). The day
after, the cells were transduced with MAO-A adenovirus.
At 48 h postsilencing, the cardiomyocytes were stimulated
for 6 h with TYR alone (500μM) or posttreated with OA
(100μM) 2h after TYR stimulation. Cells transfected with
siRNA scramble (Scr) were used as control.
2.5. MTT Assay. The cells were incubated for 3 h in a
0.5mg/ml MTT solution at 37°C. In the presence of viable
cells, MTT is converted into purple formazan crystals
insoluble in aqueous solution. Then, the MTT solution
was aspirated and 200μl/well of DMSO was added to
solubilize the formazan crystals. Blue formazan absorbance
was measured at 570nm with a spectrophotometric multi-
plate reader (Bio-Rad).
2.6. Intracellular ROS Generation. ROS generation in
cardiomyocytes was measured using the ROS-sensitive
DCFDA (2′,7′-dichlorodihydrofluorescein diacetate) fluo-
rescent probe as previously described [13].
2.7. LDH Assay. Lactate dehydrogenase (LDH) released in
the culture medium was measured as an index of cell necrosis
using the LDH Cytotoxicity Assay Kit (BioVision) according
to the manufacturer’s instructions.
2.8. Fluorescence Microscopy. Autophagic vacuole staining
was performed by the Cyto-ID® Autophagy Detection Kit
(Enzo Life Sciences) according to the manufacturer’s instruc-
tions. Live cells were analysed by fluorescence microscopy,
and the fluorescence intensity at 488 nm was quantified using
the ImageJ software (RSB). For autophagic flux assessment,
plasmid transfection with a GFP-RFP-LC3 construct was
performed using the Lipofectamine 2000 reagent (Life
Technologies). This construct allows the identification of
autophagosomes (GFP+, RFP+, yellow) and autolysosomes
(GFP−, RFP+, red) since the GFP fluorescence is lost upon
lysosomal acidification whereas the RFP fluorescence
remains stable. The cells were treated according to the
experimental protocol, fixed for 5min in 4.0% formaldehyde
solution, washed, and analysed by fluorescence microscopy.
For immunofluorescence studies, the cells were fixed in
4.0% paraformaldehyde, washed again, and incubated with
TBS/0.2% Triton for 10min at room temperature. Then,
the cells were blocked with TBS/3.0% BSA for 1 h at room
temperature and incubated overnight with anti-TFEB
antibody (Bethyl Laboratories) diluted 1 : 400 in blocking
solution. The immunoreaction was revealed using Alexa
Fluor 546 goat anti-rabbit (diluted 1 : 1000). After washing,
the slides were mounted with a cover-slip with mounting
medium containing DAPI for nuclei labelling and analysed
for TFEB translocation to the nucleus.
2.9. Western Blot. Cardiomyocytes were lysed in RIPA buffer
(10mM Tris pH7.4, 150mM NaCl, 1.0% Triton X-100, 1.0%
sodium deoxycholate, and 0.1% sodium dodecyl sulfate), and
35μg of proteins was resolved by SDS-PAGE, transferred to a
PVDF membrane (by the Trans-Blot Turbo Transfer System,
Bio-Rad), and immunoblotted overnight with the following
antibodies: anti-LC3B (CST no. 2775, 1 : 1000 dilution) or
anti-Beclin1 (CST no. 3495, 1 : 1000 dilution). Then, the blots
were incubated for 1 h with specific secondary antibodies
(1 : 10000, goat anti-rabbit and goat anti-mouse, Molecular
Probes, Life Technologies). β-Actin (Sigma-Aldrich) was
used as loading control. Immunoreactive bands were
detected by chemiluminescence with a Bio-Rad ChemiDoc
XRS+ camera. Relative densities were quantified using the
Image Lab 4.0 software (Bio-Rad).
2.10. Real-Time PCR. Cells were treated with 100μMOA for
30min in complete medium. RNA extraction from cardiac
ventricles was performed by column affinity purification
(Qiagen, Courtaboeuf, France). cDNAs were synthesized
using the SuperScript II RT-PCR system (Invitrogen) with
random hexamers. Real-time PCR was performed on a
StepOnePlus system (Applied Biosystems, Courtaboeuf,
France) in 96-well plates with specific primers and a SYBR
Green mix (Eurogentec, Angers, France). Primer sequences
were as follows: ATP6V1-F: TGTCTCTGGAGTGAATGGT
CC; ATP6V1-R: TGCCCACTTCTTTTTGTGCC; Lamp1-
F: TGACCATTGTGCTCTGGGAC; Lamp1-R: GGGAAG
GTTGATCCTGTGGG; p62 (Sqstm1)-F: CCATCAGAGGA
TCCCAATGT; and p62 (Sqstm1)-R: CGCCTTCATCC
GAGAAAC. Data were normalized using the following
primers: GAPDH-F: TCTCTGCTCCTCCCTGTTCTA and
GAPDH-R: TCCGATACGGCCAAATCCGTT.
2.11. Statistical Analysis. The results are expressed as
mean ± SEM. Experimental groups were compared using
Student’s t-test or the one-way or two-way ANOVA, when
appropriate. A value of p < 0 05 was considered significant.
3. Results
3.1. OA Induces Autophagy in Cardiomyocytes. OA has been
previously described as a potent and rapid inducer of autoph-
agy in neuroblastoma cells [25]. Thus, we sought to explore
whether OA acted in a similar way in cardiomyocytes.
Neonatal rat cardiomyocytes were exposed to 100μM OA,
a concentration lacking cell cytotoxicity up to 6 h, the longest
incubation time used in our experiments, as verified by MTT
and LDH assays (Supplemental Figure 2). At this concentra-
tion, OA did not modify baseline oxidative status measured
with DCFDA fluorescence (Supplemental Figure 2). Inter-
estingly, after 1 h of treatment with OA, a significant
increase in autophagic puncta was evidenced by fluorescence
imaging using the Cyto-ID Green dye (Figure 1(a)). Accord-
ingly, we observed that the two autophagy markers Beclin1
(Figure 1(b)) and LC3-II increased at 1 hour following OA
stimulation, suggesting early enhancement of autophagy
(Figure 1(c)).
3.2. OA Stimulation Enhances Autophagic Flux in
Cardiomyocytes. The presence of autophagic vacuoles is
not indicative of completed autophagy but can also repre-
sent a block in autophagosomal maturation; therefore, we
checked the different steps of the autophagic flux in
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response to OA in cardiomyocytes. To this aim, cells were
transfected with the RFP-GFP-LC3 plasmid, resulting in
about 30% transfection efficiency, and treated with 100μM
OA for different time periods (1 h, 3 h, or 6 h) and double
immunofluorescence imaging was performed (Figure 2(a)).
After 1 h of treatment with OA, we observed in the trans-
fected cells an increase in the number of autophagosomes
(yellow puncta), which was more pronounced at 3 h. At 6 h,
we noticed a decreased number of autophagosomes while
autolysosomes (red puncta) increased significantly. This
result suggests that OA stimulates autophagic flux in cardio-
myocytes. We next confirmed this observation by measuring
LC3-II turnover by Western blot. The cells were treated for
6 h with chloroquine (CQ, 10μM) alone, an inhibitor of
lysosome acidification, or with CQ together with OA. As
expected, the degradation of LC3-II, the mature form of
LC3 incorporated into autophagosomes, was blocked in
the presence of CQ, resulting in the accumulation of
LC3-II compared to control conditions (Figure 2(b)). In
cells treated with both CQ and OA, we found a greater
amount of LC3-II compared to CQ alone. This difference
might be due to increased autophagosome formation with
OA (Figure 2(b)). Taken together, these results indicate
that OA is an activator of autophagic flux in cardiomyocytes,
including the final steps of autophagosome-lysosome fusion
and lysosomal degradation.
3.3. OA Stimulates TFEB Nuclear Translocation and Activity.
Once established that OA stimulated autophagic flux in car-
diomyocytes, the following step was to elucidate the molecu-
lar mechanisms underlying autophagy activation. In this
scenario, it has been demonstrated that the transcription fac-
tor TFEB acts as a master regulator of autophagy and lyso-
somal genes, allowing coordination of the different steps of
autophagy and activation of the flux [31]. TFEB activity is
mainly controlled by its subcellular localization. TFEB is kept
inactive in the cytoplasm, but when it translocates to the
nucleus, it can activate the transcription of target genes
[31]. In order to evaluate the effect of OA on TFEB nuclear
translocation, we treated cardiomyocytes for 30min and
visualized TFEB subcellular localization by immunofluores-
cence staining. As shown in Figure 3(a), in untreated control
cells, only 50% of the cells displayed nuclear localization of
TFEB while after OA treatment, this percentage increased
significantly to 80%. Translocation of TFEB in the nucleus
has been demonstrated to allow the transcription of autoph-
agy genes. Thus, we decided to measure the mRNA expres-
sion of autophagic genes that are known to be direct targets
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Figure 1: OA induces autophagy in neonatal rat cardiomyocytes. (a) Rat neonatal ventricular myocytes were treated with OA (100 μM) for
1 h, and autophagic vacuoles were stained with Cyto-ID green (left panel). Nuclei were counterstained with Hoechst 33342. Scale bar 20μm.
The graph on the right panel represents quantification of fluorescence intensity (N = 3 independent experiments; for each experiment, 6 fields
with about 15 cells were quantified per condition). (b, c) Immunoblot analysis of Beclin1 and LC3 proteins was performed on cardiomyocyte
protein extracts after stimulation with OA (100 μM) for 1 h. β-Actin expression was used as loading control. The graphs represent
quantifications of Beclin1/β-actin (N = 3) and LC3-II/LC3-I ratios (N = 5) measured by densitometry analysis. ∗p < 0 05, ∗∗p < 0 01, and
∗∗∗p < 0 001 versus CTRL (control).
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of TFEB. We found that OA treatment for 30min
increased mRNA expression of Atp6v1, p62, and Lamp1,
suggesting early activation of TFEB transcriptional activity
(Figure 3(b)).
3.4. OA Protects against MAO-A Induced Cardiotoxicity.
Considering our evidence of induction of autophagic flux
by OA, we hypothesized that this polyphenol might have
beneficial effects in a cardiac model of autophagy dysfunc-
tion. In order to evaluate this possibility, we used cardiomyo-
cytes transduced with an adenovirus that drives MAO-A
expression (Ad-MAO-A) and we incubated the cells with
tyramine (TYR, 500μM), a substrate metabolized by
MAOA; to generate H2O2 [13]. In this model, upon TYR
addition, we detected a time-dependent increase in ROS pro-
duction, which was maximal at 1 h, as measured with
DCFDA probe fluorescence (Figure 4(a)). As a consequence,
mitochondrial dysfunction and cell necrosis were evidenced
2h after TYR application, as measured with MTT and
LDH assays (Figures 4(b) and 4(c)). In order to determine
if OA could alleviate the deleterious effects of MAO-A, we
first treated the cells with TYR for 2 h and then added OA
in the culture media (posttreatment) for the remaining 4 h
(Figure 5(a)). Most interestingly, cardiomyocytes subjected
to OA posttreatment displayed protection against mito-
chondrial alteration and necrotic death induced by TYR
(Figures 5(b) and 5(c)).
3.5. OA Ameliorates MAO-A-Induced Impairment of the
Autophagic Flux. Next, we sought to evaluate whether OA
could restore autophagic flux inhibition due to MAO-A acti-
vation. To this purpose, we performed the RFP-GFP-LC3
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Figure 2: OA enhances autophagic flux in neonatal rat cardiomyocytes. (a) Double immunofluorescence imaging of RFP-GFP-LC3 in
cardiomyocytes stimulated with 100 μM OA for different times (1 h, 3 h, and 6 h) (left panel). Scale bar 20 μm. Quantification of yellow
puncta (autophagosomes) and red puncta (autolysosomes) for each condition is displayed on the histogram (right panel) (N = 4
independent experiments; for each experiment, 10 cells were quantified per condition). ∗∗p < 0 01 versus CTRL; °°p < 0 01 versus CTRL;
#p < 0 05 OA 3 h versus 6 h; §§§p < 0 001 OA 3h versus 6 h. (b) Immunoblot analysis of LC3 protein was performed on cardiomyocyte
protein extracts after stimulation with chloroquine (CLQ, 10μM) or CLQ+OA (CLQ, 10μM, and OA, 100 μM) for 6 h. β-Actin
expression was used as loading control. The graphs represent quantifications of the LC3-II/LC3-I ratio measured by densitometry
analysis (N = 3). ∗∗p < 0 01 versus CTRL; ∗∗∗p < 0 001 versus CTRL; #p < 0 05 CQ versus CQ+OA.
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assay in cardiomyocytes stimulated for 6 h with TYR alone or
with TYR in the presence of OA for the last 4 h (posttreat-
ment). Stimulation of cardiomyocytes with TYR for 6 h
induced significant accumulation of yellow puncta (autopha-
gosomes), but not red puncta (autolysosomes), indicative of
defective autophagic clearance (Figure 6). However, post-
treatment with OA during the last 4 h decreased the num-
ber of autophagosomes and increased significantly the
formation of autolysosomes in TYR-treated cells (Figure 6).
We conclude that OA restores the defective autophagic flux
in stress conditions, promoting autophagosome clearance
in cardiomyocytes with MAO-A overactivation.
3.6. OA Restores Nuclear Localization of TFEB in Ad-MAO-
A-Stimulated Cardiomyocytes. Activation of MAO-A has
previously been shown to induce ROS-mediated cytoplasmic
build-up of TFEB and reduction of its transcriptional
activity, a putative mechanism by which autophagosome
clearance was inhibited [13]. We thus sought to explore
whether OA might counteract these deleterious effects of
MAO-A, by evaluating TFEB subcellular localization with
immunofluorescence staining. As expected, TYR stimula-
tion for 2 h significantly decreased the percentage of cells
with TFEB nuclear localization compared to untreated
(Figure 7). Most interestingly, posttreatment during the
last 30min with OA induced massive translocation of
TFEB into the nuclear compartment (Figure 7). These
results indicate that the ability of OA to restore the
autophagic flux may be dependent, at least in part, on
TFEB activation, which is an early event.
3.7. TFEB Activation Is Crucial for OA-Mediated Beneficial
Effects. To assess whether TFEB activation was essential
for OA protection, we performed TFEB silencing in cardi-
omyocytes by transfection with TFEB siRNA. We first
checked the efficacy of TFEB silencing by quantitative
real-time reverse transcriptase-PCR (RT-PCR) and found
a significant decrease in TFEB mRNA 24 hours after
transfection with TFEB-siRNA, compared to scramble
siRNA (SCR-siRNA)-transfected cells (Figure 8(a)). In
SCR-siRNA conditions, cardiomyocytes stimulated with
TYR for 6 h showed a decrease in MTT, which was also
observed in TFEB-siRNA conditions (Figure 8(b)). Interest-
ingly, posttreatment with OA prevented the decrease in
MTT in SCR-siRNA conditions, but this beneficial effect
was lost in TFEB-siRNA conditions (Figure 8(b)). In conclu-
sion, the presence of TFEB is necessary for OA to confer pro-
tection against the deleterious effects of MAO-A.
4. Discussion
In the present study, we report that OA regulates autoph-
agic flux in resting cardiomyocytes and restores autophagy
impairment resulting from MAO-dependent oxidative
stress, protecting cardiomyocytes from mitochondrial
dysfunction and cell death. In addition, to the best of
our knowledge, we provide the first evidence of the role
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Figure 3: OA induces TFEB translocation and activation. (a) Immunofluorescence staining with TFEB antibody in cardiomyocytes treated
with OA (100 μM) for 30min (red). Nuclei were counterstained with DAPI. Scale bar 20μm (left side). Quantification analysis of cells with
nuclear localization of TFEB in percent of total nuclei (right side) (N = 3 independent experiments; for each experiment, 6 fields with about 15
cells were quantified per condition). (b) Real-time PCR expression of Atp6v1, p62, and Lamp1 normalized to GAPDH transcript levels in
cardiomyocytes treated with OA (100 μM) (N = 6). ∗p < 0 05 versus CTRL.
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of TFEB activation in the cardioprotective effect of OA
against defective autophagy. The cardioprotective effects
of OLE and/or OA have been previously attributed to
several mechanisms such as reduction of oxidative and
nitrosative stress [32] as well as antiplatelet [33], hypolip-
idemic [34], and anti-inflammatory [35] activities. A
recent study [36] shows that OLE reduces proinflamma-
tory cytokines and increases antioxidant markers. Such
findings are similar to previous studies showing that
OLE reduces prooxidants and proinflammatory cytokines
and increases antioxidant markers in adriamycin cardio-
toxicity [32, 35] and myocardial ischemia/reperfusion [34,
37]. Another study on acute doxorubicin (DXR)-induced
cardiomyopathy suggests that OLE prevents the structural,
functional, and histopathological cardiac effects of chronic
DXR toxicity, not by a direct antioxidant effect, but
through the modulation of signalling pathways of eNOS,
iNOS, ET-1, Akt, and AMPK [35].
Autophagy is an evolutionarily conserved self-digestive
process through which cells adapt to nutrient starvation
and other stress conditions [11, 12, 38]. A major cause of
the aging process is a progressive loss of cellular quality
control mechanisms, and autophagy is an important quality
control pathway, needed to maintain cell homeostasis
(notably neuronal and cardiac) and to adapt to stress. A
reduction in autophagy has been observed in a number
of aging models, and there is compelling evidence that
enhanced autophagy delays aging and extends life span.
Enhancing autophagy counteracts age-associated accumu-
lation of protein aggregates and damaged organelles [39].
A growing number of studies focus on a causal relation-
ship between impaired autophagic flux and several diseases
including neurodegeneration, cancer, myopathy, and car-
diovascular diseases [18, 23, 27, 40]. Some data supporting
the beneficial effects of plant polyphenols in autophagy-
flux impairment were recently reported [41–43]. In our
previous studies, we showed that in neuroblastoma cells,
OA induces autophagy through activation of the Ca2+/
CaMKKβ/AMPK/mTOR signalling pathway, a mechanism
in accordance with that previously reported for other poly-
phenols [24, 25, 27]. In vivo, we found that TgCRND8
mice, a model of Aβ deposition, fed with OA-
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Figure 4: Time-course of DCFDA fluorescence, MTT, and LDH in Ad-MAO-A-transduced cardiomyocytes stimulated with TYR. Ad-
MAO-transduced cardiomyocytes were stimulated with MAO substrate TYR (500 μM) for different times (15min to 4 h) before
measuring (a) the fluorescence of DCFDA probe in a fluorimeter (N = 3), (b) MTT reduction (N = 5), and (c) LDH release in culture
supernatant (N = 5). ∗p < 0 05; ∗∗p < 0 01; ∗∗∗p < 0 001 versus CTRL.
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Figure 5: OA is protective against MAO-induced cardiotoxicity. (a) Ad-MAO-transduced cardiomyocytes were stimulated with MAO
substrate TYR (500 μM) for 6 h or with TYR+OA during the last 4 h (posttreatment) to measure (b) MTT reduction (N = 8) and (c) LDH
release in the supernatant (N = 4). ∗∗p < 0 01; ∗∗∗p < 0 001 versus CTRL.
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Figure 6: OA restores autophagic flux in Ad-MAO-A-transduced cardiomyocytes. Double immunofluorescence imaging of RFP-GFP-LC3 in
Ad-MAO-A-transduced cardiomyocytes stimulated with TYR (500 μM) for 6 h or with TYR+OA added during the last 4 h (posttreatment).
Representative images (upper panel). Scale bar 20μm. Quantification of yellow puncta (autophagosomes) and red puncta (autolysosomes) for
each condition is displayed on the histogram (lower panel) (N = 5 independent experiments; for each experiment, 10 cells were quantified per
condition). ∗∗∗∗p < 0 0001, ∗∗∗p < 0 001, and ∗p < 0 05.
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supplemented diet displayed a remarkable improvement of
the cognitive performance, a massive reduction in Aβ pla-
que number and size, and an astonishing activation of the
autophagic flux in the cortex, where increased expression
of autophagy markers was also found [27].
In this study, our first aim was to assess whether OA
induced autophagy in cardiomyocytes and, if so, to investi-
gate whether TFEB-mediated transcriptional regulation
could play a role. We showed that OA was able to induce
autophagy in cardiac cells after short times of treatment, as
shown by the increase in autophagic vacuoles and
autophagy-specific markers, such as Beclin1 and LC3-II.
However, since the accumulation of autophagosomes and
the increase of autophagy markers are not fully indicative
of effective autophagy activation but can also result from a
blockade of autophagosome maturation, we performed an
autophagic flux assay. “Autophagic flux” is a measure of
degradative completion of autophagy that requires the
autophagosome-lysosome fusion and the consequent
substrate degradation. Accordingly, complete autophagic
degradation is a condition needed to determine whether
autophagy is really protective to the cell favouring recycling
and cleaning of damaged materials and organelles. To this
purpose, in OA-treated cells we used the Tandem Sensor
RFP-GFP-LC3B, which specifically labels autophagosomes
and autolysosomes, and we found that autophagosomes were
processed to lysosomes and that autophagic flux was indeed
enhanced. Once having established that OA induced autoph-
agic flux in neonatal rat cardiomyocytes, the next step was to
explore the involvement of the master autophagy regulator
TFEB. At present, the role of OA as a TFEB activator has
not been described. Recent findings indicated that curcu-
min, another hydrophobic polyphenol, enhances autopha-
gic flux both in human colon cancer HCT116 cells and
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Figure 7: OA induces nuclear localization of TFEB in Ad-MAO-transduced cardiomyocytes. Immunofluorescence staining (red) with TFEB
antibody in cardiomyocytes treated with TYR (500 μM) for 2 h or with TYR+OA added during the last 30min (posttreatment). Nuclei are
stained with DAPI (upper panel). Scale bar 20μm. Quantification analysis of cells with nuclear localization of TFEB in percent of total nuclei
(lower panel) (N = 3 independent experiments; for each experiment, 6 fields with about 15 cells were quantified per condition). ∗p < 0 05
versus CTRL and ∗∗p < 0 01 Tyr +OA versus TYR.
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in mouse embryonic fibroblasts (MEFs) via mTOR sup-
pression and increased TFEB transcriptional activity [38].
In cardiomyocytes, we found that OA was able to induce
nuclear translocation of TFEB and, accordingly, to upreg-
ulate TFEB target genes, in particular autophagy genes
such as ATP6-V1 ATPase, p62, and LAMP1. TFEB trans-
location can be regulated by two distinct signalling path-
ways involving mTOR kinase or calcineurin phosphatase.
Under nutrient-rich conditions, TFEB is phosphorylated
by mTORC1 on the lysosomal surface, sequestered, and
complexed with 14-13-3 proteins. During starvation,
mTOR is inhibited, with decreased TFEB phosphorylation
and activation of its nuclear translocation. In addition,
under starvation, Ca2+ released from the lysosome through
the MCOLN1 channel activates the calcium-dependent
phosphatase calcineurin, which, in turn, dephosphorylates
TFEB and induces its nuclear translocation [31]. In the
present study, our results show that OA acts as a caloric
restriction mimetic, inducing TFEB translocation, eventu-
ally through mTOR or calcineurin signalling, which will
require further investigation.
Once having highlighted the ability of OA to stimulate
autophagic flux through TFEB activation in cardiomyocytes
under basal conditions, we sought to better investigate a
hypothetical protective effect of OA in stress conditions
characterized by autophagy impairment. To this purpose,
we used Ad-MAO-A-transduced cardiomyocytes, a cardiac
model of autophagy dysfunction characterized by MAO-A
overexpression. It is well known that cardiac MAO-A expres-
sion increases in rat models of HF, such as hypertension,
transverse aortic constriction, diabetes, and cardiac aging
[44–46], as well as in human ischemic cardiomyopathy [2].
These pathological conditions are associated with mitochon-
drial dysfunction and cardiac damage, but only recently,
Santin et al. [13] elucidated the reason for the accumulation
of dysfunctional mitochondria in situations of enhanced
MAO-A activity. MAO-A is responsible for the degradation
of serotonin and catecholamines in the heart and produces
H2O2 as a byproduct of the reaction. Oxidative stress by
MAO-A blocks autophagic flux through impairment of
lysosomal function, leading to accumulation of damaged
mitochondria and to cardiomyocyte necrosis [13]. In
addition, MAO-A activation prevents TFEB translocation
to the nucleus, reducing its transcriptional activity. We there-
fore wondered whether the increase in TFEB translocation by
OA might mitigate the cardiomyocyte damage caused by the
MAO-A/H2O2 axis by restoring the autophagic flux. We
found for the first time that OA was able to restore autopha-
gic flux in Ad-MAO-transduced cardiomyocytes following
massive translocation of TFEB. To exclude the hypothesis
that this effect was merely due to an antioxidant effect of
OA against MAO-produced H2O2, we transfected cardio-
myocytes with siRNA targeting TFEB. As transcriptional reg-
ulation of autophagy by OA matched with a significant
improvement of cell death and mitochondrial functionality
that disappeared after TFEB silencing, we hypothesized that
TFEB was essential for the protective effects of OA against
MAO-A-induced autophagy dysfunction. In addition, in
basal condition, OA was able to induce TFEB translocation
and autophagy induction without any effect on ROS status
in cardiomyocytes, which further highlights its properties as
an autophagy inducer.
In conclusion, there is a possibility that TFEBmodulation
may delay organ degeneration and prevent cardiac disease
through restoring functional autophagy. Recently, Sergin
et al. [15] were able to reverse autophagy dysfunction of
macrophages in atherosclerotic plaques in both tissue and
animal models by increasing TFEB function. The authors
also showed that a natural sugar, trehalose, induces macro-
phage autophagy/lysosomal biogenesis, thus recapitulating
the atheroprotective properties of TFEB overexpression in
macrophages. In line with this, we have shown that the pro-
tective effect of OA goes well beyond its known antioxidant
power, being able to effectively interfere with key signalling
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Figure 8: The protective effects of OA on MAO-A-induced toxicity are lost upon TFEB silencing. (a) Cardiomyocytes were silenced with
scramble (SCR) or TFEB siRNA, and the level of TFEB mRNA was examined 48 h posttransfection by real time-RT-PCR. Results are
normalized to GAPDH and expressed as a fold increase to SCR control siRNA (N = 3). (b) Cardiomyocytes were transfected with SCR or
TFEB-siRNA for 24 h and then transduced with MAO-A adenovirus for an additional 24 h. Then, cardiomyocytes were stimulated with
TYR (500 μM) for 6 h or TYR+OA in the last 4 h, and an MTT test was performed (N = 3). ∗p < 0 05 and ∗∗p < 0 01.
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pathways at the basis of energy metabolism and proteostasis
in cardiomyocytes. Our data suggest the possibility to use OA
as a nutraceutical in association with the current treatments
of cardiovascular diseases characterized by autophagy
dysfunction. However, as it has been outlined in a recent
review [47], the bioactivity of phenolic compounds is strictly
dependent on their bioavailability which represents a critical
issue. Concerning OA and its precursor OLE, the main vari-
ables are represented by the form in which they are ingested
(pure compounds, extracts containing different percentages
of the compounds, and whole olive oils with different pheno-
lic composition), dosage, duration of the treatment, and
association with different foods. A general consensus con-
cerns that olive oil phenols are absorbed and metabolized
by humans, because their degradation and modification
products are retrieved in urine following ingestion [48–50].
Nevertheless, absorption profiles vary, depending on the
source of such phenols [51, 52]. Moreover, OA is absorbed
more efficiently than OLE is, probably because its higher apo-
larity favours passive transport across the cell membrane
[53]. A recent report further shows that, after OLE adminis-
tration to rats, OA is retrieved both in faeces and in urine
(together with hydrolysis and modification products) [54].
Particularly relevant is the evidence suggesting that, in rats
and humans, orally administered olive oil phenols, including
OA, OLE, and/or one of its derivatives arising from tissue
metabolism, are distributed in many tissues, including heart
[48, 55]. Finally, OA and 3,4-dihydroxyphenylethanol-eleno-
lic acid dialdehyde seem to associate to membranes as a con-
sequence of their hydrophobicity [56]; this implies that they
may accumulate at the cellular level, reaching a local concen-
tration higher than that expected on the basis of their plasma
concentration.
More information, mainly in human subjects, is still
lacking for what OA and OLE effective doses pharmacoki-
netics and pharmacodynamics are concerned; however, an
increasing body of data support the possibility that long-
term treatment of aged people with olive leaf-based nutra-
ceuticals and/or EVOO enriched in OA/OLE may contrast
the symptoms of aging-related pathologies [57], including
cardiac disease, delay their appearance, or reduce their
severity.
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